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Objective: The long-term effects of surgical fibroblast growth factor 2 therapy are
examined.
Methods: In a randomized, double-blind study, fibroblast growth factor 2 (10 g or
100 g) or placebo (n  8 each) was delivered in the ungraftable myocardial
territory of patients concomitantly undergoing coronary artery bypass grafting.
Patients were followed up to 32.2  6.8 months postoperatively with clinical
assessment and nuclear perfusion imaging.
Results: Baseline patient characteristics were similar between the 3 groups. There
were 2 late deaths, one of pancreatic cancer and one of undetermined cause (both in
the 100-g fibroblast growth factor 2 group). Two patients (both in the control
group) underwent a total of 6 repeat cardiac catheterizations for recurrent coronary
events. Mean Canadian Cardiovascular Society angina class improved at late
follow-up from baseline in all groups (P  .02); however, patients treated with
either dose of fibroblast growth factor 2 had significantly more freedom from angina
recurrence than those treated with placebo (P  .03). Late nuclear perfusion scans
revealed a persistent reversible or a new, fixed perfusion defect in the ungraftable
territory of 4 of 5 patients who received placebo versus only 1 of 9 patients treated
with fibroblast growth factor 2 (P  .02). The overall sum of left ventricular stress
perfusion defect scores was also lower in fibroblast growth factor 2–treated patients
than in control subjects (1.3  1.4 vs 3.9  2.1, respectively; P  .04). A trend
toward a higher late left ventricular ejection fraction was noted in fibroblast growth
factor 2–treated patients (55.1%  14.6% vs 44.3%  6.5%, fibroblast growth
factor 2–treated patients versus control subjects; P  .12).
Conclusions: These data suggest that surgical angiogenic therapy with sustained-
release fibroblast growth factor 2 may result in a prolonged myocardial revascular-
ization effect that could translate into clinical benefit.
Therapeutic angiogenesis is a promising modality for the treatment ofpatients with end-stage diffuse coronary artery disease for whommedical therapy has failed and who are not amenable to furtherdirect coronary revascularization. Several delivery methods, includ-ing intravenous, intracoronary, or perivascular routes, have beenused in animal and clinical studies to administer either protein- or
gene-based formulations with variable success.1-5
Our group has previously reported the results of a phase I randomized controlled
trial of local perivascular delivery of fibroblast growth factor 2 (FGF-2) in patients
undergoing coronary artery bypass grafting (CABG).3 In this study, patients in
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whom high-dose FGF-2 sustained-release capsules had been
surgically implanted in an ungraftable territory at the time
of CABG had complete relief from angina and showed
significant improvements in stress nuclear perfusion defect
size at 3 months’ follow-up. These benefits were of greater
magnitude than those observed in patients who received
either placebo or low-dose FGF-2.
Although these early results appeared promising, there
are to date little published long-term safety and efficacy data
pertaining to any type of therapeutic angiogenesis modality.
Theoretically, exogenous angiogenic agents could have the
undesirable potential to stimulate intimal growth and desta-
bilize atherosclerotic plaques,6,7 enable the development of
unrecognized tumors,8 and promote other vascular pathol-
ogies, such as the formation of hemangiomas9 or the exac-
erbation of diabetic retinopathy.10 Although these potential
complications have not been reported thus far in angiogen-
esis trials, their development would likely exhibit latency
and escape clinical recognition until late follow-up is car-
ried out.
Similarly, scant animal or clinical data exist that examine
whether the effects of angiogenic therapies are long lasting.
It is conceivable that the long-term efficacy of both protein-
and gene-based delivery methods might be influenced, re-
spectively, by the limited tissue half-life of protein formu-
lations and by the high baseline levels of antibodies to
adenoviral gene-delivery vectors found in the general pop-
ulation.11 Long-term data are also needed to better delineate
the confounding role of a significant placebo effect ob-
served in several clinical trials, as well as that of myocardial
inflammation on the angiogenic response.4 To better ascer-
tain some of these safety and efficacy issues, we conducted
a long-term clinical and nuclear imaging follow-up study of
patients previously enrolled in a phase I randomized con-
trolled trial of perivascular FGF-2 delivered in an ungraft-
able myocardial territory during CABG.
Methods
Patient Selection
The initial design of the study has been previously reported.3 The
patient population consisted of patients undergoing CABG at Beth
Israel Deaconess Medical Center (Boston, Mass) and Montefiore
Medical Center (Bronx, NY). Inclusion criteria included the dem-
onstration of an ischemic, viable myocardial territory supplied by
a major coronary artery considered by both a cardiothoracic sur-
geon and an interventional cardiologist to be unamenable to bypass
grafting or percutaneous intervention on the basis of its angio-
graphic appearance. Ungraftability was also determined intraoper-
atively by a noninvestigator cardiac surgeon before confirmation
of eligibility. Patients with clinically significant valvular disease,
left ventricular ejection fraction of less than 20%, serum creatinine
level of greater than 2.5 mg/dL, a history of malignancy in the
previous 5 years, or a severe fixed nuclear perfusion defect in the
ungraftable territory were excluded from the study.
The design and performance of the study were approved by the
Food and Drug Administration under an investigational new drug
protocol (BB-IND 5725), as well as by the Committee for Clinical
Investigation at both institutions. The first patient was enrolled in
September 1996 and the last patient in May 1998. Follow-up was
completed in March 2001.
Preparation and Delivery of FGF-2
Sterile sustained-release heparin-alginate capsules containing ei-
ther placebo or 10 or 100 g of human recombinant FGF-2 (Scios,
Sunnyvale, Calif) were prepared as previously described.3,12,13
During aortic crossclamping, after completion of coronary bypass
grafts to all revascularizable areas of the heart (including the
routine construction of a left internal thoracic artery anastomosis to
the left anterior descending artery and saphenous vein bypasses to
other graftable territories) and failure to graft the target artery,
intraoperative implantation of heparin-alginate capsules was per-
formed. To this end, multiple linear incisions were made in the
epicardial fat surrounding the target vessel, and 10 capsules con-
taining either 1 of 2 doses of FGF-2 or placebo were inserted into
the epicardial fat adjacent to the artery (2-3 capsules in each
incision) and secured in place with a 6-0 polypropylene suture, as
previously described.14 Patients were subsequently weaned from
cardiopulmonary bypass, and routine closure was performed. The
surgeon, other investigators, and patients were blinded to treat-
ment-group assignments.
Clinical Follow-Up
Subsequent to in-hospital and early follow-up, the methods of
which have been previously reported,3 patients were contacted
yearly postoperatively to record the occurrence of major clinical
events (death, myocardial infarction, recurrent angina, or repeat
revascularization) and to determine their angina status according to
the Canadian Cardiovascular Society (CCS) classification. In the
third year after the operation, patients were brought back to their
study center for a history, physical examination, and laboratory
evaluation that included complete blood count, serum chemistries,
urinalysis, and rest electrocardiography. Clinical follow-up was
complete, with a mean duration (for patients who survived the
perioperative period) of 32.2 6.8 months (range, 23-44 months).
Nuclear Perfusion Imaging
In addition to clinical follow-up, patients underwent dual-isotope
studies with thallium (rest) and dipyridamole sestamibi (pharma-
cologic stress) before CABG (first 10 patients) or postoperatively
before discharge from the hospital (last 14 patients) and 3 months
later. Patients were subsequently invited to return for a late nuclear
assessment in their third or fourth postoperative year, with the
exception of one patient in the control group in whom a midterm
scan performed for symptoms of recurrent myocardial ischemia
had revealed a new fixed defect in the ungraftable territory. All late
nuclear assessments were done with a gated SPECT protocol and
interpreted by a single nuclear medicine physician (J.A.P.) blinded
to the territory of implantation and treatment-group assignments.
Stress and rest perfusion scans for all 3 time points were assessed
during one reading session, and myocardial images were subdi-
vided into 5 myocardial regions (septal, anterior, lateral, inferior,
and apical). Each territory was given a score of 0 (no defect), 1
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(mild), 2 (moderate), or 3 (severe defect). For a given territory, a
score difference of 1 or more observed between separate studies
was considered to be reflective of a change in myocardial perfu-
sion, and a given defect was considered to exhibit a reversible
component if a score difference of 1 or more points between stress
and rest perfusion images was noted at a given study.
Left ventricular ejection fraction was calculated from gated
wall-motion images obtained approximately 45 minutes after di-
pyridamole administration. Late nuclear studies were completed
between 23 and 44 months (mean, 30.6  9.0 months) after
operation in 5 of 7 surviving patients in the control group, 5 of 8
surviving patients in the 10-g FGF-2 group, and 4 of 6 surviving
patients in the 100-g FGF-2 group.
Statistical Methods
Continuous data are expressed as means  SD. Ordinal data, such
as angina class, are expressed as median (2.5th percentile, 97.5th
percentile). Statistical analyses were performed with nonparamet-
ric methods, with data pertaining to patients who survived the
perioperative period. Angina class data were longitudinally com-
pared within each group by using a Wilcoxon signed-rank test, as
well as between groups by using a Kruskal-Wallis test. Angina
class and left ventricular ejection fraction data were also compared
between the placebo and combined FGF-2 treatment groups by
using the Wilcoxon rank-sum test. Bonferroni corrections were
applied on all tests involving repeated measures. Postoperative
freedom from angina recurrence was assessed with the Kaplan-
Meier method and compared between placebo and combined FGF-
2–treated patients with a log-rank test. Dichotomous variables
were compared with a Fisher exact test. All reported probability
values are 2-tailed, and P values of less than .05 were considered
statistically significant.
Results
Patient Characteristics
Of 78 patients screened for enrollment into the study, a total
of 24 patients who met eligibility criteria and accepted to
take part in it were confirmed at the time of the operation to
have one ungraftable coronary artery supply in ischemic and
viable myocardial territory. These patients were randomized
intraoperatively to receive 10 heparin-alginate capsules con-
taining either 10 g of FGF-2 (n  8), 100 g of FGF-2
(n  8), or placebo (n  8). Preoperative patient charac-
teristics are summarized in Table 1. With the exception of
older age in the groups of patients who received 10 g and
100 g of FGF-2 and a higher proportion of women in the
10-g FGF-2 group, no significant difference was observed
between the study groups in any of the preoperative clinical
parameters.
Short-Term Results
Previously reported short-term results are summarized in
Table 2.3 The implantation territory corresponded to the
right coronary artery distribution in 15 patients, the left
circumflex distribution in 7 patients, and the diagonal sys-
tem in 2 patients. There was no significant difference in the
number of grafts performed or total operative time between
the 3 groups. One patient in the 100-g FGF-2 group who
had a preoperative left ventricular ejection fraction of 20%
could not be weaned from cardiopulmonary bypass and died
intraoperatively. At autopsy, all grafts were patent.
Postoperatively, one patient in the control group died 24
hours after the operation after an autopsy-documented sa-
phenous vein graft occlusion and a new large myocardial
infarction in the subtended territory. Two other patients
(both in the control group) required intra-aortic balloon
pump support after the operation (in one patient the intra-
aortic balloon pump was inserted preoperatively). Two pa-
tients (one in the control group and one in the 10-g FGF-2
group), who subsequently declined to undergo late nuclear
perfusion studies, had new Q waves in the ungraftable
myocardial distribution, and one patient in the 10-g FGF-2
group had a Q-wave myocardial infarction in a bypassed
territory. Placement of heparin-alginate FGF-2 capsules did
not significantly affect acute hemodynamic parameters, se-
rum chemistries, hematologic and coagulation profiles, liver
function test results, or urinalysis.3
Clinical Follow-Up
Two late deaths occurred in the 22 patients who survived
the perioperative period, both of whom were in the 100-g
TABLE 1. Baseline patient characteristics
Placebo
(n  8)
FGF-2, 10 g
(n  8)
FGF-2, 100 g
(n  8)
Age (y) 47.4 11.4 58.8 10.3 60.2 10.1
Male/female (n) 7/1 4/4 8/0
Hypertension (n) 4 3 4
Tobacco use (n) 3 4 5
Cholesterol 200 mg/dL (n) 4 3 5
Diabetes (n) 4 3 5
Prior CABG (n) 0 2 1
Three-vessel disease (n) 7 8 8
Pre-CABG LVEF (%) 53.6 14.7 53.0 11.3 44.4 15.1
LVEF, Left ventricular ejection fraction.
Cardiopulmonary Support and Physiology Ruel et al
30 The Journal of Thoracic and Cardiovascular Surgery ● July 2002
CSP
FGF-2 group (P .09). The first patient, a 72-year-old man
with a history of severe peripheral vascular disease and
renal insufficiency, had complete resolution of his angina
postoperatively but died suddenly 24 months after the op-
eration. There was no consent to autopsy. The second pa-
tient, a 68-year-old man, died of metastatic pancreatic ade-
nocarcinoma 37 months postoperatively. This patient had
undergone implantation of 100-g FGF-2 capsules in the
distribution of an ungraftable right coronary artery.
Two patients (both in the control group) experienced
recurrent unstable angina, for which they underwent a total
of 6 repeat coronary angioplasty procedures. Angioplasty
and stenting were successful in achieving revascularization
of myocardial distributions subtending a failed saphenous
vein bypass graft but could not successfully revascularize
the ungraftable territory in either patient. The 2 patients
went on to have electrocardiographic evidence of myocar-
dial infarction in the ungrafted territory and were free of
angina at late follow-up.
For the 22 patients who survived the perioperative pe-
riod, data pertaining to angina severity and postoperative
freedom from recurrent angina are presented in Table 3 and
Figure 1, respectively. Although all groups of patients ex-
perienced functional benefits at late follow-up when com-
pared with baseline values (P  .02 for any of the 3 groups,
Table 3), patients treated with either dose of FGF-2 had
significantly more freedom from recurrent angina postoper-
atively than those treated with placebo (P  .03, Figure 1).
There was no significant difference in CCS class at late
follow-up or freedom from angina recurrence between pa-
tients who were treated with capsules containing 10 g
versus 100 g of FGF-2.
Nuclear Perfusion Imaging
Results of late nuclear perfusion follow-up scans are pre-
sented in Table 4. In the control group all scanned patients
but one had either a persistent reversible defect or a new
fixed defect in the ungraftable territory, which was in con-
trast to only 1 of 9 patients who had been treated with either
dose of FGF-2 (one patient in the 10-g and none in the
100-g group, P  .02). The sum of stress perfusion defect
scores for all myocardial territories was also lower in FGF-
2–treated patients than in control subjects (P .04). A trend
toward a higher late left ventricular ejection fraction was
noted in patients who were treated with FGF-2 versus that
seen in control subjects by a magnitude of approximately
10% in ejection fraction units (P  .12). No statistically
significant difference was observed between the low-dose
and high-dose FGF-2–treated groups in any of the above
parameters.
TABLE 2. Short-term results
Placebo (n  8)
FGF-2, 10 g
(n  8)
FGF-2, 100 g
(n  8)
Implanted coronary distribution (n)
RCA 3 7 5
LCX 3 1 3
Diagonal 2 0 0
No. of grafts (n) 3.1 1.3 3.0 0.9 3.1 0.8
Duration of the operation (h) 2.9 0.6 3.0 0.9 3.2 1.2
Operative death (n) 1 0 1
Perioperative myocardial infarction (n) 1 2 0
RCA, Right coronary artery; LCX, left circumflex artery.
TABLE 3. CCS angina class at baseline, 6 months, and late follow-up
Placebo FGF-2, 10 g FGF-2, 100 g P value*
Median CCS angina class†
Baseline 3 (2, 4) 3 (2, 4) 3 (2, 4) .58
6 mo 2 (0, 4) 1 (0, 2) 0 (0, 2) .03
Late F/U 1 (0, 2)‡ 0 (0, 1) 0 (0, 1) .11
P value§ (last F/U vs baseline) .02 .01 .01
F/U, Follow-up.
*P value applies to control subjects versus combined FGF-2–treated patient groups at same time points (Wilcoxon rank-sum test).
†Data expressed as median (2.5th percentile, 97.5th percentile).
‡Two patients in the control group underwent repeated percutaneous coronary angioplasties for recurrent angina between the 6-month and 3-year
follow-up assessments.
§P value applies to class improvements within each patient group between baseline and late follow-up (Wilcoxon signed-rank test).
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Discussion
In this study patients in whom an ungraftable territory was
treated concomitantly to CABG with perivascular adminis-
tration of sustained-release FGF-2 capsules experienced sig-
nificantly greater freedom from angina recurrence than con-
trol patients at a mean follow-up approaching 3 years. On
late nuclear imaging studies, all but one patient in the
control group had either persistence of a reversible perfu-
sion defect or evidence of a new fixed defect in the ungraft-
able myocardial territory, whereas this was observed in only
1 of 9 patients treated with FGF-2. The remaining FGF-2–
treated patients had disappearance of their ungraftable ter-
ritory reversible perfusion defect and stability or decrease in
the size of their fixed defect (when one was present) com-
pared with that seen at baseline. FGF-2–treated patients also
showed better late global left ventricular perfusion scores
during pharmacologic stress. Finally, a trend toward higher
left ventricular ejection fraction was noted in FGF-2–treated
versus control patients at late follow-up. These results sug-
gest that perivascular angiogenic therapy combined with
CABG might play a role in alleviating ischemia and pre-
serving the function of ungraftable, ischemic, and viable
myocardial territories in the late postoperative period.
The occurrence of 2 late deaths in the high-dose FGF-
2–treated group, albeit not statistically significant, nonethe-
less constitutes a source for concern regarding the long-term
safety of angiogenic therapy. Because there was no consent
for one patient to undergo autopsy and another died as a
result of a metastatic pancreatic cancer that was diagnosed
postoperatively, the possibility that perivascular FGF-2
therapy might have contributed to these deaths, despite a
highly specific tissue distribution,15 cannot be excluded.
Previous Related Work
No published clinical trial of angiogenic therapy currently
exists that sheds light onto key issues of dose response,
duration of effect, or long-term safety with this approach.
Despite a number of limitations, our study provides some
preliminary information in this regard. In the previously
reported short-term results of this patient cohort, a signifi-
cant and dose-dependent effect of FGF-2 therapy was sug-
gested by the finding of decreased perfusion defect size on
stress nuclear imaging in patients who had received high-
dose perivascular FGF-2.3 The 3-year results reported here
also suggest persistence of an overall FGF-2–related effect,
but a dose relationship was not observed, possibly because
of the study’s sample size limitations.
Short- and long-term results of intramyocardial angio-
genic therapy with FGF-1 have been previously reported by
another group.16,17 In this study FGF-1 was injected directly
into the myocardium along a diffusely diseased left anterior
descending coronary artery to which the left internal tho-
racic artery was also grafted. Patients were subsequently
followed up 3 years postoperatively with clinical examina-
tion, echocardiography, and selective imaging of the left
internal thoracic artery with digital subtraction angiography.
Although a local increase in collateral blush was observed
along the left anterior descending coronary artery, the study
did not report functional assessments of myocardial perfu-
sion, data pertaining to changes in CCS angina class or
freedom from angina, or the cause or timing of late deaths.
The FIRST trial recently evaluated the effects of intra-
coronary FGF-2 therapy in a large, double-blind phase II
study involving 337 patients.18 Ninety-day follow-up re-
vealed a significant improvement in angina frequency in
patients treated with 3.0-g/kg FGF-2 but no significant
change in ejection fraction or in the size of ischemic terri-
tories on nuclear perfusion imaging. It is conceivable that
the effects of FGF-2 in the FIRST trial, along with those of
vascular endothelial growth factor in the preceding VIVA
trial,19 might have been somewhat compromised by the
choice of intracoronary and intravenous delivery routes,
which are nonspecific in their tissue distribution. As shown
in a previous study from our group, total cardiac-specific
activity of vascular endothelial growth factor at 1 hour after
injection was only 0.88% for intracoronary and 0.26% for
intravenous administration and further decreased to 0.05%
and 0.04%, respectively, at 24 hours.20 Moreover, concern
remains that the use of these delivery routes might actually
worsen atherosclerosis because angiogenic growth factors
stimulate endothelial cell proliferation and could potentially
result in plaque expansion or instability when present in the
diseased coronary circulation.6 On the other hand, surgical
perivascular delivery might carry the additional, although
theoretic, advantage of promoting the development of sub-
epicardial collaterals between ischemic and normally per-
fused myocardium potentiated at surgical implantation by
targeting the transition zone between collateral-dependent
and normally perfused myocardial territories.
Figure 1. Freedom from recurrent angina by treatment group from
the time of CABG. Patients treated with either dose of FGF-2 had
significantly less angina recurrence postoperatively than those
who received placebo (P  .03, log-rank test).
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Limitations
This study has several limitations. Although clinical fol-
low-up is complete, some patients did not undergo late
nuclear study imaging and consequently cannot be ac-
counted for in some analyses. Conclusions must also be
tempered with the possibility that confounding factors, such
as intrinsic myocardial collateralization caused by chronic
ischemia, might have influenced group comparability or
results. The performance of 6 repeat revascularization pro-
cedures on 2 control group patients has resulted in their
complete relief from angina before the conduct of late
follow-up and might have biased against the demonstration
of additional functional or nuclear imaging benefits in the
FGF-2–treated versus placebo groups. Finally, the potential
confounding effects of CABG on angina severity, perfusion
of the ungraftable territory, and ejection fraction are also
inherent to the study design. In this regard the possibility
exists that a bypass graft might significantly increase per-
fusion to a distant myocardial territory through pre-existing
or newly formed collaterals, regardless of the effects of
angiogenic therapy. Baseline nuclear perfusion imaging
studies were performed shortly after CABG in a majority of
patients, as opposed to preoperatively, to partially limit this
confounding factor.
Despite the aforementioned shortcomings, we hope that
this study might bring preliminary insight into the long-term
safety and efficacy of perivascular angiogenic therapy. As
the field of therapeutic angiogenesis evolves, its results will
necessitate elucidation and confirmation through long-term
animal studies and phase III clinical trials.
We thank Constantin Yiannoutsos, PhD, for his statistical re-
view of the manuscript, and Deanna Niemann, RN, for her help
with the conduct of follow-up evaluations.
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Discussion
Dr Todd K. Rosengart (Evanston, Ill). I would like to con-
gratulate the authors on a very nice presentation. I would like to
emphasize the point that the author has made, which I think is
critical, that although this is an encouraging study, the limitations
of a small sample size and the confounding effects of coronary
bypass cannot be discounted, and in fact, I think it is important to
take these factors into account in terms of using caution in judging
these results.
I think that taken together, however, with the growing clinical
body of information that now includes more than a half-dozen
trials looking at angiogenic therapy, several trends appear to be
increasingly more obvious. In our own study looking at adenovi-
ral-mediated transfer of vascular endothelial growth factor, again
using an intramyocardial approach, we have follow-up beyond 1
year. The trend again appears to be that intramyocardial delivery
appears to be well tolerated. In the small number of patients that
we have looked at thus far, there do not appear to be safety or
toxicity issues, either with a protein-based or a gene-based strat-
egy. And furthermore, in our follow-up in our series out to 1 year
and again in your series out to 3 years, there appear to be encour-
aging initial results in terms of efficacy in parameters, such as
angina class and treadmill.
Importantly, especially in your examination of basic FGF, there
is a significant contrast with intramyocardial delivery versus in-
tracoronary or intravenous delivery. As you pointed out, the VIVA
trial or the basic FGF trial with intracoronary delivery has shown
no evidence of benefit or very limited evidence and certainly a
significant profile in regard to toxicity. Going forward, I think that
the studies that look at intracoronary and intravenous delivery need
to be carefully distinguished from studies such as yours that look
at intramyocardial delivery. Therefore, again, there are encourag-
ing initial trends in these early trials.
I have 2 questions specifically for the authors. One is that you
have obviously gone to great lengths in using heparin-alginate
beads, with the concept of sustained delivery being important, and
I would ask you whether you have any evidence suggesting in fact
that sustained release is necessary with basic FGF. And the second
question is in regard to methodology. SPECT analysis clearly
being an important part of your study, it is important to consider
that there was just one observer, and do you have any evidence in
terms of variability of results and not reproducibility?
Dr Sellke. Thank you, Dr Rosengart. The sustained delivery is
probably not necessary. We found that in animal models a single
delivery is probably adequate. However, for optimal vessel devel-
opment, a sustained delivery is probably necessary. The SPECT
imaging was blinded to a single observer, and, to our surprise, we
did find positive results. However, there is quite a bit of variability
in this analysis of flow with SPECT imaging. Therefore in general
you either have to have a large number of patients in the sample or
some luck, as I think we had, demonstrating a positive benefit.
Dr John R. Benfield (Los Angeles, Calif). I enjoyed your
presentation greatly. We recently had the pleasure of Dr Judah
Folkman at UCLA when he gave a beautiful summary of angio-
genesis research and its potential clinical applications. I came
away from that with the understanding that in angiogenesis inhib-
itor therapy for cancer, current evidence suggests that it is symbi-
osis or the synergy between chemotherapy and angiogenesis in-
hibitors. Today you nicely listed some of the confounding factors
in your study, and these included CABG. My question is, what
about the potentially confounding factor of nonoperative treatment
of coronary atherosclerosis? How do you propose to control for
that?
Dr Sellke. Well, with concomitant coronary bypass, you are
increasing perfusion to border territories, and therefore I think it is
important to assess perfusion defects and the size of perfusion
defects after the revascularization. If you have a no-option trial,
and I think that is what you are alluding to, it is important to have
good control. That is, you need to have patients continue on
medical therapy in the control group to have a good assessment of
a real angiogenic effect. Those trials are going to be difficult to
construct and to complete, but I think that they are necessary.
Your point about cancer therapy with antiangiogenic drugs is
interesting. We actually might be causing a regression of collateral
growth with these antiangiogenic factors and vice versa. If you
give proangiogenic factors systemically to relieve cardiovascular
symptoms, you might actually be increasing the propensity of
tumors to grow.
Dr Reida M. El Oakley (Singapore). A recent report (Celletti
FL, Waugh JM, Amabile PG, Brendolan A, Hilfiker PR, Dake
MD. Vascular endothelial growth factor enhances atherosclerotic
plaque progression. Nat Med. 2001;4:425-9) showed that the over-
expression of vascular endothelial growth factor is associated with
exacerbation of atherosclerosis and expansion of atheromatous
plaques. First of all, would you care to comment on this? And
second, are you aware of any data on the effect of basic FGF on
atherosclerosis?
Dr Sellke. You are very right that angiogenic therapy, either
vascular endothelial growth factor or other growth factors, might
increase the vascularity of atherosclerotic plaques, and, at least in
theory, lead to plaque softening and an increased incidence of
plaque rupture. However, I do not think that has really been
demonstrated, either in patients or in animal models. And I am not
aware that basic FGF has been associated with that; however, that
is a theoretic possibility.
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